Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease

Authors Heike Rau-Berger, Harald Mitfessel, Thomas Glaab

Published 10 October 2010 Volume 2010:5 Pages 367—373

DOI https://doi.org/10.2147/COPD.S14082

Review by Single-blind

Peer reviewer comments 3

Heike Rau-Berger1, Harald Mitfessel2, Thomas Glaab1
1Medical Affairs Germany, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim; 2Pulmonology Practice, Remscheid, Germany

Aim: This observational study with tiotropium Respimat® was performed in a real-life setting to investigate its effectiveness with regard to physical functioning and tolerability.
Methods: Patients with chronic obstructive pulmonary disease (COPD; n = 1,230; mean age, 65.5 years) received tiotropium 5 µg once daily via Respimat® Soft Inhaler for 6 weeks in an open-label observational study. At baseline and week 6, patients completed the Physical Function subdomain [PF-10] of the Short Form (SF) 36 questionnaire.
Results: Improvement in standardized PF-10 score of ≥10 points was achieved by 61.5% of patients. Mean (SD) standardized PF-10 scores improved by 13.4 (15.9) points, from 49.0 (24.5) to 62.3 points (23.5; P < 0.001). Results in smokers (n = 435) were not significantly different to those in nonsmokers. The general condition of patients improved during treatment. Adverse events were reported by 4.0% of patients and were chiefly respiratory symptoms and dry mouth.
Conclusion: In COPD patients receiving tiotropium Respimat® in daily practice, physical function improved rapidly within 6 weeks of treatment, irrespective of smoking status.

Keywords: COPD, tiotropium, physical function, therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery

Lee JY, Kim JS, Cho HJ, Kim DD

International Journal of Nanomedicine 2014, 9:2803-2813

Published Date: 3 June 2014

Suppression of IL-8 production from airway cells by tiotropium bromide in vitro

Suzaki I, Asano K, Shikama Y, Hamasaki T, Kanei A, Suzaki H

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:439-448

Published Date: 6 September 2011

Budesonide/formoterol combination in COPD: a US perspective

Amir Sharafkhaneh, Amarbir S Mattewal, Vinu M Abraham, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:357-366

Published Date: 4 October 2010

Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease

Davood Attaran, Shahrzad M Lari, Mohammad Towhidi, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:335-340

Published Date: 30 September 2010

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

Beatrix Balint, Henrik Watz, Carolynn Amos, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:311-318

Published Date: 6 September 2010